Urogen Pharma (NASDAQ:URGN) Receives Average Rating of “Buy” from Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have received an average rating of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $32.86.

Several equities research analysts have recently commented on URGN shares. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Urogen Pharma in a research note on Tuesday, July 8th. Oppenheimer set a $31.00 target price on Urogen Pharma and gave the company a “buy” rating in a research note on Friday, June 13th. Scotiabank reissued an “outperform” rating on shares of Urogen Pharma in a research note on Friday, June 13th. The Goldman Sachs Group set a $16.00 target price on Urogen Pharma and gave the company a “neutral” rating in a research note on Friday, June 13th. Finally, D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Urogen Pharma in a research note on Monday, July 7th.

Urogen Pharma Price Performance

Urogen Pharma stock opened at $15.27 on Friday. The business has a 50 day simple moving average of $10.37 and a 200 day simple moving average of $10.50. Urogen Pharma has a one year low of $3.42 and a one year high of $17.00. The company has a market capitalization of $705.49 million, a PE ratio of -4.80 and a beta of 1.02.

Urogen Pharma (NASDAQ:URGN) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. The business had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Equities analysts anticipate that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of Urogen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total transaction of $38,043.94. Following the transaction, the insider directly owned 153,378 shares in the company, valued at approximately $1,130,395.86. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Urogen Pharma by 4.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock worth $231,000 after acquiring an additional 969 shares in the last quarter. Wellington Management Group LLP lifted its holdings in Urogen Pharma by 0.8% during the first quarter. Wellington Management Group LLP now owns 148,078 shares of the company’s stock worth $1,638,000 after acquiring an additional 1,125 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Urogen Pharma by 4.3% in the first quarter. Rhumbline Advisers now owns 53,466 shares of the company’s stock valued at $591,000 after purchasing an additional 2,196 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Urogen Pharma by 13.6% in the fourth quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock valued at $242,000 after purchasing an additional 2,727 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Urogen Pharma by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock valued at $996,000 after purchasing an additional 3,024 shares in the last quarter. 91.29% of the stock is currently owned by institutional investors.

About Urogen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.